Determinants of patient survival in cervical cancer: An overview

CME Journal of Gynecologic Oncology

Volumn 6, Issue 2, 2001, Pages 173-183

  Duarte Franco, E ^a   Franco, E L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer; Disease characteristics; Epidemiology; Patients characteristics; Prognostic factors; Survival; Treatment modalities

Indexed keywords

VIRUS DNA;

AGE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GRADING; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ENDOCRINOLOGY; FEMALE; FUNCTIONAL ASSESSMENT; HEMOGLOBIN DETERMINATION; HUMAN; LYMPH NODE METASTASIS; NUTRITION; PROGNOSIS; RACE; REVIEW; SENTINEL LYMPH NODE; SOCIOECONOMICS; TUMOR GROWTH; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0034782027     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Estimates of the worldwide mortality from twenty-five major cancers in 1990
2. Gynecologic cancers
3. Epidemiology of uterine cancers
4. Cancer patient survival by socio-economic status in seven countries: A review for six common cancer sites
5. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy
6. An international comparison of cancer survival: Toronto, Ontario, and Detroit, Michigan, metropolitan areas
7. Revisiting the effect of the Pap test on cervical cancer
8. Differences in cervical cancer mortality among black and white women
9. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina
10. Mechanistic reasoning in socio-behavioral epidemiology: The influence of race and ethnicity on cancer survival
11. Young age as a prognostic factor in cervical cancer: Results of a population-based study
12. Age, substance abuse, and survival of patients with cervical carcinoma
13. Cervical cancer practice patterns and appropriateness of therapy
14. Cervical cancer in Kerala: A hospital registry-based study on survival and prognostic factors
15. Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma
16. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design
17. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
18. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix
19. Pre-treatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies
20. Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy
21. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: A multivariate analysis
22. Body mass predicts the survival of patients with new International Federation of Gynecology and Obstetrics Stage IB1 and IB2 cervical carcinoma treated with radical hysterectomy
23. The role of tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity
24. Histopathological factors influencing pelvic lymph node metastases in two or more sites in patients with cervical carcinoma undergoing radical hysterectomy
25. Sentinel lymph node detection in patients with cervical cancer
26. Molecular quantification and mapping of lymph-node micrometastases in cervical cancer
27. Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma
28. Stage I adenocarcinoma of the cervix: Does lesion size affect treatment options and prognosis?
29. Prognosis-predicting system based on factors related to survival of cervical carcinoma
30. Lymphocyte-infiltrated FIGO stage IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival
31. Prognostic factors of adenocarcinoma of the uterine cervix
32. Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma
33. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: An analysis of 891 cases
34. Recurrence and survival analyses of 1,115 cervical cancer patients treated with radical hysterectomy
35. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation
36. Prognosis and clinicopathological characteristics of IB-IIB adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy
37. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan
38. Prognostic factors of the uterine cervix adenocarcinoma
39. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate
40. The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma
41. Prognostic factors in stage IB-IIA cervical carcinomas treated with postoperative radiotherapy
42. Microinvasive carcinoma of the cervix. Rationale for conservative treatment in early squamous cell carcinoma
43. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers
44. Advanced-stage cervix cancer: Rapid tumour growth rather than late diagnosis
45. Tumor proliferation and apoptosis in human uterine cervix carcinoma I: Correlations between variables
46. Tumour proliferation and apoptosis in human uterine cervix carcinoma II: Correlations with clinical outcome
47. Contemporary theories of cervical carcinogenesis: The virus, the host, and the stem cell
48. Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization
49. Expression of p150 in cervical neoplasia and its potential value in predicting survival
50. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma
51. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer
52. Apoptosis in cervical squamous carcinoma: Predictive value for survival following radiotherapy
53. A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma
54. Detection of apoptosis and expression of apoptosis-associated proteins as early predictors of prognosis after irradiation therapy in stage IIIb uterine cervical cancer
55. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy
56. Angiogenesis in adenocarcinoma of the uterine cervix
57. Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in cervical cancer
58. Correlation between tumor angiogenesis and expression of thymidine phosphorylase, and patient outcome in uterine cervical carcinoma
59. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
60. The prognostic significance of beta human chorionic gonadotrophin and its metabolites in women with cervical carcinoma
61. Human papillomaviruses
62. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
63. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer
64. Prognostic value of human papillomavirus in the survival of cervical cancer patients: An overview of the evidence
65. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA
66. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA
67. Squamous cell carcinoma of the cervix - HPV-16 and DNA ploidy as predictors of survival
68. Human papillomaviruses and other influences on survival from cervical cancer in Panama
69. Human papillomavirus DNA in cervical carcinoma-correlation with clinical data and influence on prognosis
70. Human papillomavirus DNA in invasive cervical carcinomas and its association with patient survival: A nested case-control study
71. Possible prognostic significance of human papillomavirus type in cervical cancer
72. Human papillo-mavirus genotype as a prognostic indicator in carcinoma of the uterine cervix
73. Papillomavirus DNA and prognosis in cervical cancer
74. Human papillomavirus genotype as a major determinant of the course of cervical cancer
75. Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types
76. Poor clinical outcome in early stage cervical cancer with human papillomavirus-18 positive lymph nodes
77. Prognostic importance of human papillomavirus type-16 DNA in cervical cancer
78. HPV- and node status in cervical cancer long-term results
79. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer
80. Cervical cancer in young women in Taiwan: Prognosis is independent of papillomavirus or tumor cell type
81. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: A prognostic study
82. Human papillomavirus and disease-free survival in FIGO stage IB cervical cancer
83. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer
84. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study
85. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
86. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
87. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
88. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
89. Treatment outcomes for squamous intraepithelial lesions
90. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: A prospective randomized study
91. Radical hysterectomy in the elderly female: A comparison to patients age 50 or younger
92. Intent-to-treat analysis of stage IB and IIA cervical cancer in the United States: Radiotherapy or surgery 1988-1995
93. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials
94. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group
95. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
96. Post-therapy surveillance of women with cervical cancer: An outcomes analysis